Table 2.
Comparison of clinical data between sarcopenic and nonsarcopenic elderly male patients with type 2 diabetes mellitus
| Clinical factor | Patients without sarcopenia (N) | Patients with sarcopenia (N) | P |
|---|---|---|---|
| Age (years) | 72.6 ± 5.6 (128) | 78.6 ± 6.6 (23) | < 0.001 |
| BMI (kg/m2) | 24.2 ± 3.3 (128) | 22.2 ± 2.7 (23) | 0.007 |
| Duration (years) | 17.1 ± 10.5 (128) | 19.4 ± 9.9 (23) | 0.330 |
| Insulin-treated patients (%) | 18.0 (23/128) | 13.0 (3/23) | 0.767 |
| Injected insulin (U/kg/day) | 0.30 ± 0.17 (23) | 0.32 ± 0.07 (3) | 0.880 |
| HbA1c (%) | 7.51 ±+1.23 (128) | 7.44 ± 0.96 (23) | 0.789 |
| Total protein (g/dl) | 7.2 ± 0.4 (109) | 7.4 ± 0.6 (18) | 0.101 |
| Serum albumin (g/dl) | 4.2 ± 0.3 (109) | 4.2 ± 0.4 (18) | 0.568 |
| LDL cholesterol (mg/dl) | 113.9 ± 27.3 (123) | 99.0 ± 30.8 (23) | 0.019 |
| HDL cholesterol (mg/dl) | 138.5 ± 143.5 (123) | 116.1 ± 80.6 (23) | 0.468 |
| eGFRcre (ml/min/1.732) | 65.8 ± 16.3 (127) | 62.5 ± 18.7 (23) | 0.374 |
| eGFRcys (ml/min/1.732) | 72.2 ± 16.4 (121) | 55.9 ± 18.3 (21) | < 0.001 |
| HS-CRP (mg/l) | 0.97 ± 0.95 (125) | 1.95 ± 2.02 (22) | < 0.001 |
| HOMA-IR | 2.41 ± 1.58 (80) | 1.98 ± 0.71 (11) | 0.374 |
| Retinopathy (%) | 21.6 (21/97) | 33.3 (4/12) | 0.466 |
| Macroangiopathy (%) | 14.8 (19/128) | 21.7 (5/23) | 0.370 |
BMI body mass index, LDL low-density lipoprotein, HDL high-density lipoprotein, eGFRcre estimated glomerular filtration rate calculated via serum creatinine, eGFRcys estimated glomerular filtration rate calculated via serum cystatin C, HS-CRP high-sensitivity C-reactive protein, HOMA-IR homeostasis model assessment for insulin resistance, Retinopathy preproliferative or proliferative diabetic retinopathy, Macroangiopathy ischemic heart disease or peripheral arterial disease